Clinical Trial Update: Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma [Phase 4]

View source ↗

Summary

This is a Phase 4 trial of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma. The study is completed and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Anaplastic Large Cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2022-05-26